NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ALUR

Allurion Technologies Inc

Jul 03 • 04:00PM ET

2.51

Dollar change -0.05
Percentage change -1.95	%

Healthcare • Medical Devices • USA • NYSE

Peers: ABT SYK MDT BSX ILMN BDX ZBH DXCM PODD TNDM

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.38	Insider Own	10.61%	Shs Outstand	7.46M	Perf Week	0.40%
Market Cap	18.72M	Forward P/E	-	EPS next Y	-1.92	Insider Trans	2.06%	Shs Float	6.67M	Perf Month	-11.93%
Enterprise Value	31.29M	PEG	-	EPS next Q	-0.81	Inst Own	38.71%	Short Float	3.75%	Perf Quarter	-25.07%
Income	-24.36M	P/S	0.66	EPS this Y	89.63%	Inst Trans	2.06%	Short Ratio	0.77	Perf Half Y	-77.93%
Sales	28.30M	P/B	-	EPS next Y	-58.76%	ROA	-49.50%	Short Interest	0.25M	Perf YTD	-76.65%
Book/sh	-11.70	P/C	0.92	EPS next 5Y	32.53%	ROE	-	52W High	33.75 -92.56%	Perf Year	-91.04%
Cash/sh	2.74	P/FCF	-	EPS past 3/5Y	- -892.33%	ROIC	-	52W Low	2.15 16.74%	Perf 3Y	-98.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	65.16%	Volatility	4.35% 6.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.11	EPS Y/Y TTM	88.34%	Oper. Margin	-135.26%	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.88	Sales Y/Y TTM	-41.98%	Profit Margin	-86.05%	RSI (14)	48.01	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.09	EPS Q/Q	-92.92%	SMA20	-0.53%	Beta	-0.47	Target Price	10.62
Payout	-	Debt/Eq	-	Sales Q/Q	-40.55%	SMA50	-2.43%	Rel Volume	0.07	Prev Close	2.56
Employees	137	LT Debt/Eq	-	Earnings	May 14 BMO	SMA200	-65.78%	Avg Volume	323.09K	Price	2.51
IPO	Mar 29, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	192.82% 1.45%	Trades		Volume	22,551	Change	-1.95%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-02-24	Initiated	TD Cowen	Buy	$2
Sep-06-24	Initiated	ROTH MKM	Buy	$2
Feb-09-24	Initiated	Jefferies	Buy	$5

Jun-17-25 08:00AM	Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS (Business Wire)
May-29-25 04:05PM	Allurion to Present at Jefferies Global Healthcare Conference (Business Wire)
May-27-25 07:51PM	Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results (Insider Monkey) -8.99%
04:05PM	Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program (Business Wire)
May-22-25 09:36AM	Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies (Zacks)
11:37AM	Loading…
May-21-25 11:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks) -11.29%
May-15-25 03:12AM	Allurion Technologies Inc (ALUR) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-14-25 10:25AM	Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates (Zacks) +23.73%
08:00AM	Allurion Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-13-25 05:15PM	MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss (Business Wire)
09:55AM	What To Expect From Allurion Technologies Inc (ALUR) Q1 2025 Earnings (GuruFocus.com)
May-08-25 06:45PM	ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-07-25 06:55PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-05-25 04:05PM	Allurion to Report First Quarter 2025 Financial Results on May 14, 2025 (Business Wire)
08:52AM	Loading…
Apr-17-25 08:52AM	4 Medical Product Stocks to Buy From a Challenging Industry (Zacks)
Apr-03-25 04:30PM	Allurion Announces Postponement of Special Meeting of Stockholders (Business Wire) -6.87% -7.05%
Mar-26-25 10:44AM	Allurion Technologies Inc. (ALUR) Q4 2024 Earnings Call Transcript (SeekingAlpha)
09:15AM	Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-20-25 04:59PM	Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment (SeekingAlpha) -5.00% +57.02%
04:05PM	Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence (Business Wire)
Mar-12-25 04:05PM	Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025 (Business Wire) +8.09%
Mar-04-25 04:05PM	Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity (Business Wire) -8.77%
Feb-25-25 04:05PM	Allurion to Participate in Upcoming Investor Conferences (Business Wire) +7.06%
Feb-20-25 04:05PM	Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline (Business Wire) -7.69%
Feb-19-25 09:03AM	Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline (Business Wire) -30.11%
Feb-18-25 08:30AM	Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity (Business Wire) +8.35%
Feb-13-25 08:30AM	Allurion Relaunches in France (Business Wire)
Feb-10-25 09:55AM	How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67% (Zacks) -8.61%
04:15PM	Loading…
Jan-24-25 04:15PM	Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk (Investor's Business Daily) +134.86% -21.17%
11:28AM	Allurion Catapults Nearly 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk (Investor's Business Daily)
10:32AM	Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement (GuruFocus.com)
09:30AM	Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market (Business Wire)
Jan-23-25 03:48PM	Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program (Business Wire) +21.31%
Jan-21-25 08:30AM	Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity (Business Wire)
Jan-14-25 09:18AM	Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024 (Business Wire) +5.72%
Jan-08-25 08:00AM	Allurion Announces Positive Topline Results From AUDACITY Trial (Business Wire) -7.42%
Dec-24-24 07:00AM	Allurion Technologies, Inc. Announces Reverse Stock Split (Business Wire) +12.33%
Dec-19-24 03:57PM	FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next (Yahoo Finance) -9.74%
Dec-02-24 08:00AM	Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance (Business Wire)
Nov-25-24 02:51PM	Allurion launches compounded GLP-1 program as FDA aims to ends access (Yahoo Finance)
02:51PM	Allurion launches compounded GLP-1 program as FDA aims to end access (Yahoo Finance)
08:00AM	Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program (Business Wire)
Nov-13-24 08:00AM	Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -26.34%
Nov-04-24 08:10AM	Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Societys Annual Conference (Business Wire)
Oct-30-24 08:30AM	Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024 (Business Wire) -5.13%
Oct-23-24 08:00AM	Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon (Business Wire)
Oct-09-24 08:00AM	Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss (Business Wire)
Oct-01-24 08:04AM	Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss (Business Wire)
Sep-05-24 05:30PM	Allurion Receives Continued Listing Standards Notice from NYSE (Business Wire) -5.56%
08:00AM	Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity (Business Wire)
Sep-03-24 08:00AM	Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors (Business Wire)
Aug-28-24 08:28AM	Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program (Business Wire) +5.42%
Aug-20-24 08:00AM	Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial (Business Wire) +5.02%
Aug-15-24 04:05PM	Allurion Receives Continued Listing Standards Notice from NYSE (Business Wire)
Aug-13-24 08:00AM	Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-16-24 04:05PM	Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024 (Business Wire) -6.37%
Jun-28-24 09:06AM	Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement (Business Wire) -23.26%
Jun-26-24 08:36AM	Allurion Announces Launch of Offering of Common Stock and Warrants (Business Wire) -16.58%
Jun-20-24 03:49PM	Why Is Allurion (ALUR) Stock Up 140% Today? (InvestorPlace) +145.28%
08:00AM	Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss (Business Wire)
Jun-14-24 01:44PM	Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy (Zacks) -11.51%
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
09:35AM	Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:00AM	Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery (Business Wire)
Jun-05-24 08:00AM	Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer (Business Wire)
May-30-24 08:00AM	Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s (Business Wire) -5.62%
May-29-24 04:05PM	Allurion to Participate in Two Upcoming Investor Conferences in June 2024 (Business Wire)
May-15-24 08:00AM	Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss (Business Wire) -9.00%
May-14-24 12:53PM	ALUR Stock Earnings: Allurion Technologies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +8.76%
08:00AM	Allurion Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-02-24 08:00AM	Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey (Business Wire) -6.38%
Apr-30-24 08:30AM	Allurion Announces Preliminary First Quarter 2024 Results (Business Wire)
Apr-17-24 08:31AM	Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments (Business Wire) -8.05%
Apr-04-24 08:00AM	Allurion Expands Virtual Care Suite to the United States (Business Wire) +78.03%
Mar-21-24 12:53PM	ALUR Stock Earnings: Allurion Technologies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:00AM	Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (Business Wire)
Mar-13-24 08:30AM	Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference (Business Wire) +6.04%
Mar-12-24 08:00AM	Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair (Business Wire)
Mar-04-24 08:30AM	Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024 (Business Wire) -8.31%
Feb-20-24 04:05PM	Allurion to Participate in Cowens 44th Annual Health Care Conference (Business Wire) +7.47%
Feb-08-24 08:30AM	Allurion to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference (Business Wire)
Jan-29-24 08:00AM	Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies (Business Wire)
Jan-23-24 09:04AM	Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss (Business Wire)
08:15AM	World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss (Business Wire)
Jan-17-24 08:00AM	Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships (Business Wire)
Jan-11-24 08:00AM	Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities (Business Wire)
Jan-08-24 08:00AM	Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook (Business Wire)
Jan-05-24 08:00AM	New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program (Business Wire)
Jan-02-24 08:00AM	Allurions Digital Platform Gains Traction with Expanded Strategic Partnership (Business Wire) -5.61%
Nov-13-23 08:00AM	Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-06-23 04:05PM	Allurion to Participate in the Jefferies London Healthcare Conference (Business Wire) -7.08%
08:00AM	Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-11-23 08:00AM	Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon (Business Wire)
Oct-04-23 08:00AM	Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023 (Business Wire)
Sep-18-23 08:00AM	Allurion Featured at the 2023 International Bariatric Club Oxford University World Congress (Business Wire) +8.00%
Aug-29-23 08:00AM	Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach (Business Wire)
Aug-28-23 08:00AM	Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress (Business Wire)
Aug-04-23 01:33PM	Allurion sees tailwind from weight loss drug frenzy (Yahoo Finance)

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gaur Shantanu	Chief Executive Officer	May 19 '25	Buy	3.06	8,000	24,484	16,000	May 21 04:15 PM
Gaur Shantanu	Chief Executive Officer	Mar 28 '25	Buy	3.35	8,000	26,800	8,000	Apr 01 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALUR

Allurion Technologies Inc

Upgrade your FINVIZ experience